While long-term safety and cardiovascular outcome data remain under investigation, current clinical results position retatrutide as a potential paradigm shift among next-generation incretin-based medications
In a randomized trial of 95 T2DM patients with body mass index (BMI) 27 kg/m 2 , liraglutide reduced EAT levels by 29% and 36% after 3 months and 6 months, respectively, in patients receiving liraglutide plus metformin compared with those receiving metformin monotherapy [87]
The GLP-1 receptor effect on gut motility GLP-1 receptor activation is the primary driver of gastrointestinal side effects in retatrutide, just as it is in pure GLP-1 agonists like semaglutide and dual agonists like tirzepatide
Most patients benefit from drinking water consistently throughout the day, especially before meals
On average, members who logged in to the GLP-1 Success Program at least 4 days each week (n=2,349) lost 4.29% body weight, and members who never logged in to the app (n=3,842) lost 2.66% body weight in 4 weeks